Transarterial Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma Patients: Outcome Assessment Applying a Prognostic Score

• Published in: Cancers Vol. 14; no. 21; p. 5324
• Main Authors: Schatka, Imke, Jochens, Hans V., Rogasch, Julian M. M., Walter-Rittel, Thula C., Pelzer, Uwe, Benckert, Julia, Graef, Josefine, Feldhaus, Felix W., Gebauer, Bernhard, Amthauer, Holger
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 29.10.2022; MDPI
• Subjects: Albumin; Angina pectoris; Ascites; Asymptomatic; Cholangiocarcinoma; Health aspects; Laboratories; Liver; Medical imaging; Medical prognosis; Metastasis; Methods; Patients; Portal vein; Response rates; Risk factors; Scintigraphy; Survival; Therapeutic embolization; Thrombosis; Tumors; Yttrium; Germany; overall survival; prognostic score; Radioembolization; Y-90 microspheres; intrahepatic cholangiocarcinoma; liver metastases
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14215324

Radioembolization (RE) is a viable therapy option in patients with intrahepatic cholangiocarcinoma (ICC). This study delineates a prognostic score regarding overall survival (OS) after RE using routine pre-therapeutic parameters. A retrospective analysis of 39 patients (median age, 61 [range, 32–82] years; 26 females, 13 males) with ICC and 42 RE procedures was conducted. Cox regression for OS included age, ECOG, hepatic and extrahepatic tumor burden, thrombosis of the portal vein, ascites, laboratory parameters and dose reduction due to hepatopulmonary shunt. Median OS after RE was 8.0 months. Using univariable Cox, ECOG ≥ 1 (hazard ratio [HR], 3.8), AST/ALT quotient (HR, 1.86), high GGT (HR, 1.002), high CA19-9 (HR, 1.00) and dose reduction of 40% (HR, 3.8) predicted shorter OS (each p < 0.05). High albumin predicted longer OS (HR, 0.927; p = 0.045). Multivariable Cox confirmed GGT ≥ 750 [U/L] (HR, 7.84; p < 0.001), ECOG > 1 (HR, 3.76; p = 0.021), albumin ≤ 41.1 [g/L] (HR, 3.02; p = 0.006) as a three-point pre-therapeutic prognostic score. More specifically, median OS decreased from 15.3 months (0 risk factors) to 7.6 months (1 factor) or 1.8 months (≥2 factors; p < 0.001). The proposed score may aid in improved pre-therapeutic patient identification with (un-)favorable OS after RE and facilitate the balance between potential life prolongation and overaggressive patient selection.